UPBHIGH SIGNALFINANCIAL10-K

UPB's cash position declined substantially from $325.9M to $101.6M while the company reported positive Phase 2 trial results and accelerated its Phase 3 development timeline.

The significant cash burn raises questions about runway duration as UPB prepares for expensive Phase 3 trials in both severe asthma and CRSwNP starting in Q1 2027. However, the positive clinical milestones achieved—successful Phase 2 results in both indications ahead of schedule—represent meaningful value catalysts that could support future financing or partnership opportunities.

Comparing 2026-03-26 vs 2025-03-12View on EDGAR →
FINANCIAL ANALYSIS

UPB's financial profile shows substantial cash consumption with cash and equivalents falling from $325.9M to $101.6M, driving total assets down 26.6% to $353.8M and stockholders' equity declining 27.7% to $339.8M. Revenue grew modestly to $2.9M while liabilities increased moderately to $14.0M and capital expenditures decreased significantly to $165K. The overall picture reflects an early-stage biotech company burning through cash to advance clinical programs, with the substantial cash decline creating potential financing pressure ahead of capital-intensive Phase 3 trials.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-68.8%
$325.9M→$101.6M

Cash declined 68.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Capital Expenditure
Cash Flow
-67.7%
$511K→$165K

Capex reduced 67.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Stockholders Equity
Balance Sheet
-27.7%
$469.9M→$339.8M

Equity decreased 27.7% — buybacks or losses reducing book value, monitor solvency ratios.

Total Assets
Balance Sheet
-26.6%
$481.7M→$353.8M

Total assets contracted 26.6% — asset sales, write-downs, or balance sheet optimization underway.

Current Assets
Balance Sheet
-26.6%
$479.2M→$351.8M

Current assets declined 26.6% — monitor working capital adequacy and short-term liquidity.

Current Liabilities
Balance Sheet
+25.3%
$10.7M→$13.5M

Current liabilities rose 25.3% — increased short-term obligations, watch current ratio.

Revenue
P&L
+20.4%
$2.4M→$2.9M

Revenue growing 20.4% — solid top-line momentum, watch margins for quality of growth.

Total Liabilities
Balance Sheet
+18%
$11.9M→$14.0M

Liabilities increased 18% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-12
ADDED
governmental agencies, new or increased tariffs and retaliatory tariffs, trade protection measures, economic sanctions and economic slowdowns or recessions, and inflation; our ability to attract, hire, and retain our key personnel and additional qualified personnel; our anticipated use of our existing cash, cash equivalents and short-term investments; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and i other risks and uncertainties, including those listed under the caption Risk Factors.
We have advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma, including a long-term safety and efficacy extension study ( Phase 2 LTE ), chronic rhinosinusitis with nasal polyps ( CRSwNP ), and chronic obstructive pulmonary disease ( COPD ).
We reported positive top-line results in our CRSwNP Phase 2 trial in September 2025 and positive top-line results in our severe asthma Phase 2 trial in February 2026.
We plan to initiate dosing in Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027, prioritizing a Phase 3 development strategy that focuses on maximizing efficacy in both indications, without biomarker restriction, with quarterly at-home administration.
There are seven biologics approved for the treatment of severe asthma; four of these biologics are also approved for CRSwNP, and two are also approved for the treatment of COPD.
+7 more — sign up free →
REMOVED
We have advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps ( CRSwNP ) and have initiated planning activities for a Phase 2b trial in chronic obstructive pulmonary disease ( COPD ).
We completed enrollment in our CRSwNP Phase 2 clinical trial in January 2025 and expect to report top-line data from this trial in the second half of 2025, enabling regulatory discussions and preparations for a Phase 3 program in CRSwNP.
We anticipate reporting top-line data from our severe asthma Phase 2 trial in the second half of 2026 and plan to dose the first patient in our COPD program in the second half of 2025.
There are six biologics approved for the treatment of severe asthma; three of these are also approved for CRSwNP.
One biologic was recently approved for the treatment of COPD.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →